Ertapenem: Difference between revisions
Ostermayer (talk | contribs) |
|||
| (15 intermediate revisions by 7 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: [[Carbapenems]] | *Type: [[Is DrugClass::Carbapenems]] | ||
*Dosage Forms: IM, IV | *Dosage Forms: IM, IV | ||
*Common Trade Names: Invanz | *Common Trade Names: Invanz | ||
*Has activity against ESBL organisms | |||
*As opposed to [[meropenem]], ertapenem does not cover [[Pseudomonas aeruginosa]] | |||
==Adult Dosing== | ==Adult Dosing== | ||
| Line 16: | Line 18: | ||
*[[UTI]], complicated = x 10-14 days | *[[UTI]], complicated = x 10-14 days | ||
*Gynecologic = x 3-10 days | *Gynecologic = x 3-10 days | ||
*Prophylaxis, colorectal | *Prophylaxis, colorectal surgery = x 1 dose | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===General (3mo-12 years)=== | ===General (3mo-12 years)=== | ||
* | *30mg/kg/day IM/IV divided BID x 5-14 days | ||
*First Dose: | *First Dose: 15mg/kg IM/IV x 1 | ||
*Max: 1 g/day | *Max: 1 g/day | ||
*For duration, see adult specific indication dosing | *For duration, see adult specific indication dosing | ||
| Line 64: | Line 66: | ||
*Hypertension | *Hypertension | ||
*Tachycardia | *Tachycardia | ||
*Drug rash with eosinophilia | *Drug rash with [[eosinophilia]] | ||
===Common=== | ===Common=== | ||
| Line 134: | Line 136: | ||
| ||[[Klebsiella]] sp||'''S''' | | ||[[Klebsiella]] sp||'''S''' | ||
|- | |- | ||
| ||E. coli/Klebsiella ESBL+||'''S''' | | ||E. coli/Klebsiella ESBL+||'''[[Has ESBL::S]]''' | ||
|- | |- | ||
| ||E coli/Klebsiella KPC+||R | | ||E coli/Klebsiella KPC+||R | ||
| Line 217: | Line 219: | ||
*[[Antibiotics]] | *[[Antibiotics]] | ||
== | ==References== | ||
<references/> | |||
[[Category:Pharmacology]] | |||
[[Category:ID]] | |||
Latest revision as of 19:09, 19 July 2025
General
- Type: Carbapenems
- Dosage Forms: IM, IV
- Common Trade Names: Invanz
- Has activity against ESBL organisms
- As opposed to meropenem, ertapenem does not cover Pseudomonas aeruginosa
Adult Dosing
General
- 1g IM/IV daily x 5-14 days
- First Dose: 1g IM/IV x 1
Specific Indications
- 1g IM/IV daily for all
- Intrabdominal infections x 5-14 days
- Skin Infections = x 7-14 days
- Pneumonia, community aquired x 10-14 days
- UTI, complicated = x 10-14 days
- Gynecologic = x 3-10 days
- Prophylaxis, colorectal surgery = x 1 dose
Pediatric Dosing
General (3mo-12 years)
- 30mg/kg/day IM/IV divided BID x 5-14 days
- First Dose: 15mg/kg IM/IV x 1
- Max: 1 g/day
- For duration, see adult specific indication dosing
General (>13 Years)
See adult dosing
Special Populations
- Pregnancy Rating: B
- Lactation: Safety unknown
- Renal Dosing
- Adult
- CrCl <30: 500mg daily
- Hemodyalisis: give 150mg supplement if maintenance dose <6h prior
- Pediatric
- CrCl <30: decrease dose 50%
- Hemodyalisis: give 150mg supplement if maintenance dose <6h prior
- Adult
- Hepatic Dosing (Adult & Pediatric)
- No data
Contraindications
- Allergy to class/drug
- Hypersensitivity to amide anesthetics (IM only)
Cautions
- Hypersensitivity to Beta-Lactam
- Seizure history
- CNS disorder
- Renal impairment
- Recent antibiotic associated colitis
Adverse Reactions
Serious
- Hypersensitivity Reaction
- Anaphylaxis
- Neurotoxicity
- Seizures
- C. diff
- Superinfection
- Extravasation with tissue damage
- Hallucinations
- Hypertension
- Tachycardia
- Drug rash with eosinophilia
Common
- Diarrhea
- Infusion site reaction
- Nausea and Vomiting
- Transaminitis
- Headache
- Fever
- Altered Mental Status
- Constipation
- Abdominal Pain
- Edema
- Insomnia
- Thrombocytosis
- Dyspnea
- Rash
- Dizziness
- Puritis
- Hypotension
- Vaginitis
Pharmacology
- Half-life: 4h
- Metabolism: CYP450
- Excretion: Urine (80%)
- Mechanism of Action: Bactericidal
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014